Tisagenlecleucel Is Safe and Effective in Relapsed/Refractory Follicular Lymphoma

被引：0
|
作者：
Fowler, N. H.
Dickinson, M.
Dreyling, M.
Martinez-Lopez, J.
Kolstad, A.
Butler, J.
机构：
来源：
CANCER DISCOVERY | 2022年 / 12卷 / 03期
关键词：
D O I：
10.1158/2159-8290.CD-RW2022-004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Tisagenlecleucel is safe and effective for adults with pretreated relapsed/refractory follicular lymphoma (FL). ©2022 American Association for Cancer Research.
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
    Fowler, Nathan Hale
    Dickinson, Michael
    Dreyling, Martin
    Martinez-Lopez, Joaquin
    Kolstad, Arne
    Butler, Jason
    Ghosh, Monalisa
    Popplewell, Leslie
    Chavez, Julio C.
    Bachy, Emmanuel
    Kato, Koji
    Harigae, Hideo
    Kersten, Marie Jose
    Andreadis, Charalambos
    Riedell, Peter A.
    Ho, P. Joy
    Perez-Simon, Jose Antonio
    Chen, Andy, I
    Nastoupil, Loretta J.
    von Tresckow, Bastian
    Ferreri, Andres Jose Maria
    Teshima, Takanori
    Patten, Piers E. M.
    McGuirk, Joseph P.
    Petzer, Andreas L.
    Offner, Fritz
    Viardot, Andreas
    Zinzani, Pier Luigi
    Malladi, Ram
    Zia, Aiesha
    Awasthi, Rakesh
    Masood, Aisha
    Anak, Oezlem
    Schuster, Stephen J.
    Thieblemont, Catherine
    NATURE MEDICINE, 2022, 28 (02) : 325 - +
  • [2] Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
    Nathan Hale Fowler
    Michael Dickinson
    Martin Dreyling
    Joaquin Martinez-Lopez
    Arne Kolstad
    Jason Butler
    Monalisa Ghosh
    Leslie Popplewell
    Julio C. Chavez
    Emmanuel Bachy
    Koji Kato
    Hideo Harigae
    Marie José Kersten
    Charalambos Andreadis
    Peter A. Riedell
    P. Joy Ho
    José Antonio Pérez-Simón
    Andy I. Chen
    Loretta J. Nastoupil
    Bastian von Tresckow
    Andrés José María Ferreri
    Takanori Teshima
    Piers E. M. Patten
    Joseph P. McGuirk
    Andreas L. Petzer
    Fritz Offner
    Andreas Viardot
    Pier Luigi Zinzani
    Ram Malladi
    Aiesha Zia
    Rakesh Awasthi
    Aisha Masood
    Oezlem Anak
    Stephen J. Schuster
    Catherine Thieblemont
    Nature Medicine, 2022, 28 : 325 - 332
  • [3] Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma
    Salles, Gilles
    Schuster, Stephen J.
    Dreyling, Martin H.
    Fischer, Luca
    Kuruvilla, John
    Patten, Piers E. M.
    Von Tresckow, Bastian
    Smith, Sonali M.
    Ubieto, Ana Isabel Jiminez
    Davis, Keith L.
    Anjos, Carla
    Chu, Jufen
    Zhang, Jie
    Bodoni, C. Lobetti
    Thieblemont, Catherine
    Fowler, Nathan H.
    Dickinson, Michael
    Martinez-Lopez, Joaquin
    Wang, Yucai
    Link, Brian K.
    BLOOD, 2021, 138
  • [4] Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
    Salles, Gilles
    Schuster, Stephen J.
    Dreyling, Martin
    Fischer, Luca
    Kuruvilla, John
    Patten, Piers E. M.
    von Tresckow, Bastian
    Smith, Sonali M.
    Jimenez-Ubieto, Ana
    Davis, Keith L.
    Anjos, Carla
    Chu, Jufen
    Zhang, Jie
    Bodoni, Chiara Lobetti
    Thieblemont, Catherine
    Fowler, Nathan H.
    Dickinson, Michael
    Martinez-Lopez, Joaquin
    Wang, Yucai
    Link, Brian K.
    BLOOD ADVANCES, 2022, 6 (22) : 5835 - 5843
  • [5] Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
    Saha, Aditi
    Jhaveri, Khushali
    Sarfraz, Humaira
    Chavez, Julio C.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, : 869 - 876
  • [6] Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
    Saha, Aditi
    Jhaveri, Khushali
    Sarfraz, Humaira
    Chavez, Julio C.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023,
  • [7] Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
    Dreyling, Martin
    Fowler, Nathan Hale
    Dickinson, Michael
    Martinez-Lopez, Joaquin
    Kolstad, Arne
    Butler, Jason
    Ghosh, Monalisa
    Popplewell, Leslie
    Chavez, Julio C.
    Bachy, Emmanuel
    Kato, Koji
    Harigae, Hideo
    Kersten, Marie Jose
    Andreadis, Charalambos
    Riedell, Peter A.
    Ho, P. Joy
    Perez-Simon, Jose Antonio
    Chen, Andy I.
    Nastoupil, Loretta J.
    von Tresckow, Bastian
    Ferreri, Andres Jose Maria
    Teshima, Takanori
    Patten, Piers E. M.
    Mcguirk, Joseph P.
    Petzer, Andreas L.
    Offner, Fritz
    Viardot, Andreas
    Zinzani, Pier Luigi
    Malladi, Ram
    Paule, Ines
    Zia, Aiesha
    Awasthi, Rakesh
    Han, Xia
    Germano, Davide
    O'Donovan, Darragh
    Ramos, Roberto
    Maier, Harald J.
    Masood, Aisha
    Thieblemont, Catherine
    Schuster, Stephen J.
    BLOOD, 2024, 143 (17) : 1713 - 1725
  • [8] Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma
    Hao, Yanni
    Hsu, Wei-Chun
    Parzynski, Craig S.
    Degtyarev, Evgeny
    Hampson, Lisa, V
    Masood, Aisha
    Wu, Wen-Hsing
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (07)
  • [9] Treatment of relapsed or refractory follicular Lymphoma Tisagenlecleucel: EU Approval as Third-line Therapy
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (7-8)
  • [10] Zanubrutinib - Relapsed or refractory follicular lymphoma
    Grant-Monlouis-Felicite, Fiona
    Diop, Nadia
    BULLETIN DU CANCER, 2024, 111 (06) : 542 - 544
12345